Retatrutide vs tirzepatide: what the trials actually show

Retatrutide and tirzepatide get mentioned in the same breath, and it is easy to see why. Both are injectable, incretin based compounds studied for large weight changes, both are dosed once weekly, and both climb through a slow titration. But they are not the same molecule, and the trial data set them apart.

How they differ

Tirzepatide works on two receptors, GLP-1 and GIP. Retatrutide adds a third, glucagon, which is thought to raise energy expenditure on top of the appetite and insulin effects. In plain terms, tirzepatide is a dual agonist and retatrutide is a triple agonist.

What the trials showed

In SURMOUNT-1, tirzepatide produced average weight loss of roughly 15, 19 and 21 percent at 5, 10 and 15 mg weekly over 72 weeks. In its phase 2 trial, retatrutide reached about 24 percent at 48 weeks on the 12 mg weekly arm, the deepest figure reported in this class at the time. These were not head to head studies, and they differ in length and design, so treat the comparison as a rough sense of scale rather than a contest.

Titration

Both ramp up slowly to keep the gut settled. Tirzepatide starts at 2.5 mg weekly and steps up 2.5 mg every four weeks. Retatrutide's phase 2 climbed 1, 2, 4, 8, then 12 mg in four week blocks, and the faster jumps drove much more nausea.

Where things stand

Tirzepatide has an approved product behind it, so its human data are well documented. Retatrutide is still investigational. Neither is sold here, and everything above is drawn from the published trials, not from any product claim.